Test Price
600 AED✅ Home Collection Available
CBFB-MYH11 (Inv(16)) Qualitative Test in UAE | 600 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Transport and VIP Mobile Phlebotomy.
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The CBFB-MYH11 (Inv(16)) Qualitative test detects the inv(16)(p13.1q22) genetic fusion crucial for classifying acute myeloid leukemia with favorable prognosis. This targeted molecular assay is the gold standard for risk stratification and therapeutic decision-making in AML patients.
| Feature | Our Test: CBFB-MYH11 Qualitative | Alternative: NGS Pan‑Leukemia Panel |
|---|---|---|
| Precision & Sensitivity | 99.9% diagnostic sensitivity (targeted RT‑qPCR) | Variable sensitivity; may require additional confirmatory testing |
| Methodology | Real‑Time PCR (qPCR) – gold‑standard fusion transcript detection | Whole Genome Sequencing (WGS) – broad but slower, not all fusions equally covered |
| Turnaround Time | 3–4 business days | 10–14 business days, often longer due to complex bioinformatics |
Physician Insight & Safety Protocols
“As a Consultant Medical Genetics, I emphasize that detecting the CBFB-MYH11 fusion is critical for risk stratification in acute myeloid leukemia. A positive result indicates a favorable prognosis and guides targeted chemotherapy protocols. However, comprehensive clinical correlation and haematologist consultation remain mandatory for treatment decisions.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Clinical Advisory: Medication Adherence & Result Interpretation
Medication Warning (Federal Decree-Law No. 4 of 2016 on Medical Liability)
Do not alter or discontinue prescribed medications based solely on genetic test results. All treatment modifications must be overseen by the managing physician in accordance with UAE medical liability standards.
Safety Exclusion Criteria & Emergency Red Flags
Patient Safety Protocol
- Absolute contraindications: active bleeding disorder, severe thrombocytopenia (platelets <20,000/µL), haemodynamic instability.
- Inability to provide informed consent or uncontrolled infection at proposed phlebotomy site.
- Post‑collection ER red flags: excessive or prolonged bleeding, expanding haematoma, fever, redness, pus, or severe pain at the puncture site.
- Systemic warning signs: new‑onset severe bone pain, unexplained fever, bleeding gums or bruising – seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. Is a doctor’s prescription required for the CBFB-MYH11 test?
Yes, a valid DHA‑licensed doctor’s prescription is mandatory for this test to be conducted in the UAE. Referring physicians must provide a clinical history to ensure appropriate test utilization.
2. How long does it take to receive CBFB-MYH11 results?
Results are typically available within 3 to 4 working days after the specimen reaches our lab for analysis. Urgent processing may be available upon request.
3. Does insurance cover the CBFB-MYH11 test?
Most UAE medical insurance policies cover this leukemia genetic test when prescribed by a licensed haematologist or oncologist. Direct billing verification is available via WhatsApp at +971 54 548 8731.
4. What is the sample collection procedure for this test?
Standard peripheral whole blood is collected via our VIP Mobile Phlebotomy service. For bone marrow aspirates, collection is performed exclusively at our partner hospital facilities under strict sterile protocols.
UAE Regulatory & Data Privacy Adherence
Your Data is Protected Under UAE Law
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Your genetic and health data is processed under strict confidentiality and security safeguards. You retain the right to access, correct, and request deletion of your personal data.
Federal Law No. 2 of 2019 on the Use of Information and Communication Technology in Health Fields: All clinical health information is managed in compliance with UAE's legal framework for health data, ensuring secure digital storage and transmission.
Clinical Safety (Federal Decree-Law No. 4 of 2016 on Medical Liability): All specimen collections and clinical procedures adhere strictly to UAE standards of care, patient consent protocols, and medical liability regulations.
Clinical & Logistical Metadata
| Test Name | CBFB-MYH11 (Inv(16)) Qualitative Test |
| Price (AED) | 600 |
| Turnaround Time | 3–4 Business Days |
| Sample Type / Matrix | Peripheral Whole Blood |
| Methodology Used | Real-Time PCR (qPCR) |
| ICD-10-CM Code | C92.0 |
| LOINC Code | 31626-8 |
| DHA Facility License & Address | License: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians